Literature DB >> 23919473

Device factors affecting pulmonary delivery of dry powders.

Chad C Smutney1, Marshall Grant, P Spencer Kinsey.   

Abstract

The use of orally inhaled dry powder technologies is one way of delivering medicines to the lung for treating local conditions or for achieving systemic effect. These involve dry powder formulations containing an active pharmaceutical ingredient together with inhaler devices. These powder/device systems enable patients to inhale and aerosolize the medicine into suitably sized particles that deposit in the lung. Several inhaler centric aspects of these delivery systems are presented and discussed in context of new product development. Case examples are provided to highlight several inhaler aspects and to guide development of powder/inhaler systems.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23919473     DOI: 10.4155/tde.13.77

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  2 in total

Review 1.  Drug-targeting methodologies with applications: A review.

Authors:  Clement Kleinstreuer; Yu Feng; Emily Childress
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

2.  Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus.

Authors:  Marshall Grant; Tim Heise; Robert Baughman
Journal:  Clin Pharmacokinet       Date:  2021-11-13       Impact factor: 5.577

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.